Health
hs-CRP and Aging
hs-CRP measures low-grade inflammation. At 2 mg/L or higher, it flags added heart risk and can tip a statin decision. Genetics suggest CRP itself isn't a cause.
Inflammation has become one of the big ideas in aging research, and hs-CRP is the blood test most people can actually order to measure it. That’s a lot of weight for one small protein made by the liver to carry. If you’re looking into hs-CRP and aging, the test answers one question well and several others less clearly. To make sense of it, Humanic Blue follows three threads: marker, possible cause and treatment target.
Put simply, high-sensitivity C-reactive protein (hs-CRP) measures low-grade inflammation. Higher levels predict cardiovascular events: in a 30-year study of initially healthy U.S. women, women in the highest fifth of readings had more cardiovascular events than women in the lowest fifth, after accounting for other risk factors. The 2026 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline uses a level of 2 milligrams per liter (mg/L) or more on two successive occasions, with no identifiable cause, to support high-intensity statin therapy for adults at borderline 10-year risk. But genetic evidence suggests CRP itself does not cause coronary heart disease. It is a signal of inflammation, not the inflammation itself. For living longer and better, hs-CRP is a useful cardiovascular risk marker, but no trial has shown that lowering this number by itself extends life.
Key Takeaways
- Higher hs-CRP is associated with cardiovascular events and deaths from causes both related and unrelated to blood vessels in large observational studies.
- Genetic studies suggest CRP itself is unlikely to cause heart disease; it marks inflammation from other sources.
- In selected adults without known cardiovascular disease whose LDL (low-density lipoprotein) cholesterol was below 130 milligrams per deciliter (mg/dL) and hs-CRP was at least 2 mg/L, the statin rosuvastatin reduced cardiovascular events in the JUPITER trial. It lowered both LDL cholesterol and CRP, so the trial cannot separate their effects.
- Anti-inflammatory drug results depend on the drug and population: canakinumab reduced recurrent events but increased fatal infections; low-dose colchicine helped in two coronary-disease trials but not when started soon after a heart attack in the CLEAR trial.
- A 2025 ACC scientific statement advocates broad hs-CRP screening, while the formal 2026 guideline gives a specific treatment rule when hs-CRP is measured in borderline-risk adults. These documents differ in purpose and scope.
- No trial shows that lowering hs-CRP itself extends lifespan.
What does the hs-CRP test measure?
C-reactive protein is made by the liver when the body is inflamed. Standard CRP tests detect the large rises seen with infection. The high-sensitivity version detects the much smaller, persistent elevations linked to cardiovascular risk.
According to MedlinePlus, CRP can be raised by infections, inflammatory bowel disease, autoimmune disorders and lung diseases; smoking and some environmental exposures can also raise it. Obesity, insomnia, depression and menopausal hormone therapy are associated with higher levels too. That is why a single result needs context, and why the 2026 guideline asks for an elevated reading on two successive occasions with no identifiable underlying cause.
As a marker: what hs-CRP predicts
Across many studies. The Emerging Risk Factors Collaboration combined studies of people without vascular disease. Higher CRP was associated with more coronary heart disease, strokes caused by blocked blood vessels, and deaths from causes both related and unrelated to blood vessels, even after accounting for conventional risk factors.
The authors noted that CRP was also associated with death from several cancers and from lung disease, and that it isn’t clear why CRP would matter to such a wide range of conditions. They also found that the link to heart disease depends heavily on conventional risk factors and other markers of inflammation.
Over 30 years. In the Women’s Health Study, led by Paul Ridker of Brigham and Women’s Hospital, women had hs-CRP, LDL cholesterol and lipoprotein(a), or Lp(a), an inherited heart-risk marker, measured once. Higher readings of each marker were associated with more major cardiovascular events over the next three decades. Each marker added information beyond the others. This was an observational study of women starting around middle age, not an individual prediction or a treatment trial. Why Lp(a) matters is covered in What Is Lipoprotein(a)?
Is hs-CRP itself a cause?
This is where the story takes a turn. If CRP itself damaged arteries, people genetically programmed to make more of it should have more heart disease. The C-Reactive Protein Coronary Heart Disease Genetics Collaboration examined genetic variants that raise CRP. People carrying those variants did not have the higher heart-disease risk that would be expected if CRP itself were a cause.
The genetic result was consistent with CRP being a marker rather than even a modest causal factor in coronary heart disease. In other words, CRP rises with inflammation that may matter, but merely changing the marker does not establish clinical benefit.
What difference does it make whether CRP marks inflammation or causes cardiovascular harm?
As a target: what lowering inflammation has done
A statin, in people with relatively low LDL cholesterol. JUPITER found fewer cardiovascular events and deaths with rosuvastatin in participants with elevated hs-CRP. Diabetes was more common, and the trial stopped early. Because rosuvastatin lowered both LDL and CRP, the result cannot show how much benefit came from either change alone.
An anti-inflammatory drug. CANTOS found fewer repeat cardiovascular events at one dose of canakinumab without lowering cholesterol. More fatal infections and no clear reduction in overall mortality complicated that result. Novartis funded the trial; this is evidence about a specific treatment in heart-attack survivors, not a reason to treat an isolated CRP result.
Colchicine, where the setting matters. In LoDoCo2, low-dose colchicine reduced cardiovascular events among people with chronic coronary disease. A separate trial after a recent heart attack, COLCOT, also found fewer cardiovascular events. But in CLEAR, starting colchicine soon after a heart attack lowered CRP without reducing the main combined measure of cardiovascular events; diarrhea was more common. These trials involved different populations and treatment windows. They do not establish the hs-CRP number itself as a treatment target.
The US Food and Drug Administration (FDA) approved Lodoco, a 0.5 mg colchicine tablet, in June 2023 to reduce cardiovascular events in adults with established atherosclerotic disease (plaque buildup in arteries) or multiple cardiovascular risk factors. That indication does not make colchicine appropriate for an isolated high hs-CRP result; the prescribing label includes conditions in which the drug must not be used, along with potentially serious interactions with other medicines.
Which trial details would help separate lowering a marker from improving a health outcome?
How does current guidance use hs-CRP?
The 2026 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline uses hs-CRP narrowly. In adults without cardiovascular disease whose estimated 10-year risk of heart attack, stroke or other atherosclerotic cardiovascular disease (ASCVD), calculated using the PREVENT equations, is borderline (3% to under 5%), an hs-CRP of 2 mg/L or more on two successive occasions, without an identifiable cause, supports high-intensity statin therapy. The formal evidence grading appears in the Sources below.
The American College of Cardiology’s inflammation statement has a broader screening ambition. An ACC summary describes the 2025 scientific statement as recommending hs-CRP screening both before a first cardiovascular event (primary prevention) and in people with established cardiovascular disease (secondary prevention).
The statement itself also cautions that not every trial of anti-inflammatory therapy in secondary prevention has succeeded.
These documents have different jobs. The scientific statement argues for broader measurement; the formal guideline supplies a specific treatment recommendation for borderline-risk primary prevention when hs-CRP is measured. That is a scope difference, not proof of a settled universal-screening standard across all professional groups.
What’s Interesting
hs-CRP shows how a biomarker can be highly predictive without being a cause. The genetic data argue against CRP itself causing coronary disease, yet higher CRP was associated with a larger relative difference in cardiovascular risk than higher LDL in one large cohort. That comparison does not make CRP a replacement for cholesterol testing. The explanation is that CRP reflects upstream inflammation from many sources, such as excess weight, smoking, poor sleep and chronic disease. That makes it a useful alarm. It also means that pushing down the reading without addressing the source may not change the outcome. Think of a smoke detector: taking the battery out makes the kitchen quieter, but it tells you nothing about the toast.
What This Means in Practice
For living longer and better, the guidelines treat hs-CRP as one input to overall heart-risk assessment.
The long-term findings come from women followed from middle age, JUPITER enrolled selected adults without known cardiovascular disease whose LDL was below 130 mg/dL, and CANTOS and CLEAR enrolled people who had already had a heart attack. Where someone falls among those groups, and what else might be raising their CRP, shapes what the same reading means.
- Would the result change a decision? The 2026 guideline describes a statin decision for a defined borderline-risk group.
- Could another condition explain the reading? Infection, injury and the other influences listed by MedlinePlus can raise CRP. The guideline’s treatment rule requires two elevated results with no identifiable underlying cause; a clinician can determine whether and when confirmation applies.
- What do the other risk markers show? LDL cholesterol, ApoB (a marker of cholesterol-carrying particle numbers) and Lp(a) supply different information, as covered in What Is ApoB?
- What outcome did a product study measure? A lower hs-CRP result alone does not establish fewer cardiovascular events or a longer life.
A primary care clinician can interpret hs-CRP with your overall risk. A preventive cardiologist can help with borderline or complicated cases.
Bottom Line
hs-CRP measures low-grade inflammation and predicts cardiovascular events, including over 30 years in women. Genetic evidence suggests CRP itself is not a cause, so the test works as a warning light. In JUPITER, rosuvastatin reduced events in selected adults with LDL below 130 mg/dL and hs-CRP of 2 mg/L or more, but it lowered both LDL and CRP. Anti-inflammatory drug results vary by drug, disease stage and population: canakinumab and low-dose colchicine have each reduced events in particular coronary-disease trials, while CLEAR was neutral. The 2026 U.S. guideline uses repeated hs-CRP results for a narrow borderline-risk statin decision; an ACC scientific statement argues for broader screening. No trial establishes that lowering hs-CRP itself extends life.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01What part of "hs-CRP and Aging" surprised you most, or made you want to ask a better question?
- 02Which distinction in the article would be most useful to carry into everyday life?
- 03What would you want Humanic Blue to unpack next from this topic?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- Higher hs-CRP predicts cardiovascular events and non-vascular death. Supported.
- CRP itself is unlikely to cause heart disease. Supported.
- In selected adults without known cardiovascular disease whose LDL was below 130 mg/dL and hs-CRP was 2 mg/L or more, rosuvastatin reduced cardiovascular events and all-cause death during JUPITER’s abbreviated follow-up. Supported (single large RCT that stopped early).
- The 2026 guideline uses persistent hs-CRP of 2 mg/L or more to support statins at borderline risk. Established (guideline).
What We Don’t Know
- Whether lowering inflammation, separately from cholesterol, extends human lifespan. Unknown. CANTOS showed no difference in all-cause death.
- Which anti-inflammatory approach works best, and for whom. Contested.
- Whether broad screening improves clinical outcomes compared with selective testing. Unknown; the scientific statement advocates broad screening, while the formal guideline gives a targeted action rule if hs-CRP is measured.
- What an “optimal” hs-CRP for longevity is. Unknown; no such target has been established.
Detailed trial results
Pooled observational data: The Emerging Risk Factors Collaboration combined 54 studies covering 160,309 people without vascular disease. Each threefold-higher CRP was linked to 37% higher coronary heart disease risk after adjusting for conventional risk factors. It was also linked to 27% higher ischemic stroke risk, 55% higher vascular death and 54% higher non-vascular death.
Women’s Health Study: 27,939 women with an average age of 54.7 had hs-CRP, LDL cholesterol and lipoprotein(a) measured once and were followed for 30 years. Comparing the top fifth with the bottom fifth, hs-CRP carried a 70% higher risk of major cardiovascular events, a larger gap than LDL (36%) or Lp(a) (33%). Each marker added independent information.
Genetic analysis: The CRP genetics collaboration tested whether CRP-raising genetic variants also raised heart-disease risk in 194,418 people from 47 studies. Gene variants raised CRP by up to 30% per copy, but heart disease risk didn’t change (risk ratio 1.00).
Colchicine trial comparison: In LoDoCo2, 5,522 people with chronic coronary disease were followed for a median 28.6 months; the primary cardiovascular outcome occurred in 6.8% with low-dose colchicine and 9.6% with placebo. A separate recent-heart-attack trial, COLCOT, also found fewer composite cardiovascular events. But in CLEAR, 7,062 people who started colchicine soon after a heart attack were followed for a median three years: CRP fell, while the primary outcome did not (9.1% versus 9.3%), and diarrhea was more common. These are different populations and treatment windows, not proof that the hs-CRP number itself is a treatment target.
Here, a composite endpoint combines several specified cardiovascular events into one trial outcome. HR means hazard ratio, a comparison of event rates over follow-up; below 1 favors the treatment group. These ratios describe relative differences, not percentage-point reductions in an individual’s risk.
A statin, in selected people with LDL below 130 mg/dL. The JUPITER trial randomized 17,802 apparently healthy adults with LDL under 130 mg/dL and hs-CRP of 2 mg/L or more to rosuvastatin or placebo. It stopped early, after a median of 1.9 years. Rosuvastatin cut LDL by 50% and hs-CRP by 37%. The combined cardiovascular endpoint fell 44% (HR 0.56), and death from any cause fell 20% (HR 0.80). Physician-reported diabetes was more common with the statin. Because the drug lowered both LDL and CRP, the trial can’t separate the two effects.
A pure anti-inflammatory drug. In CANTOS, 10,061 heart-attack survivors with hs-CRP of 2 mg/L or more received canakinumab, which blocks the inflammatory signal interleukin-1β, or placebo. The 150 mg dose reduced repeat cardiovascular events by 15% without changing cholesterol. But canakinumab was linked to more fatal infections, and all-cause mortality didn’t differ (HR 0.94). Novartis funded the trial. The drug isn’t approved for heart disease.
Colchicine. In CLEAR, 7,062 patients started colchicine or placebo soon after a heart attack. CRP fell, but the primary cardiovascular outcome didn’t (9.1% vs. 9.3%; HR 0.99), and diarrhea was more common. CLEAR tested colchicine only after a heart attack, so its result doesn’t settle the drug’s role in other settings.
Sources
- 2026 ACC/AHA dyslipidemia guideline — Current U.S. clinical-practice guideline. For adults without ASCVD at borderline PREVENT-ASCVD 10-year risk (3% to under 5%), it gives a Class 2a, B-R recommendation for high-intensity statin therapy when hs-CRP is at least 2 mg/L on two successive occasions with no identifiable cause. This is a treatment recommendation in a defined group, not a universal screening mandate.
- MedlinePlus CRP test — National Library of Medicine patient guidance, reviewed June 2025. Supports what CRP and hs-CRP measure and lists infection, inflammatory disease, smoking, some environmental exposures, obesity, insomnia, depression and menopausal hormone therapy as influences. It does not establish a longevity target.
- Emerging Risk Factors Collaboration — Individual-participant meta-analysis of 54 prospective studies, 160,309 people without vascular disease and 1.31 million person-years. Higher CRP was associated with coronary disease, ischemic stroke and vascular and nonvascular mortality after adjustment; observational associations do not establish that CRP causes those outcomes.
- Women’s Health Study 30-year analysis — Prospective cohort of 27,939 initially healthy U.S. women, mean baseline age 54.7, followed for 30 years. The adjusted hazard ratio for a first major cardiovascular event was 1.70 for the top versus bottom hs-CRP fifth. One baseline measurement, women only and observational design limit individual prediction and causal inference; NIH funded the study.
- CRP genetics collaboration — Mendelian-randomization meta-analysis of 194,418 people from 47 studies, including 46,557 with prevalent or incident coronary disease. CRP-raising variants changed CRP by up to 30% per allele but the combined genetically predicted coronary-risk ratio was 1.00 (95% CI 0.90–1.13). The analysis addresses coronary disease, not every possible role of inflammation.
- JUPITER — Randomized trial of 17,802 apparently healthy men and women with LDL below 130 mg/dL and hs-CRP at least 2 mg/L. It stopped early after a median 1.9 years; rosuvastatin reduced the primary cardiovascular endpoint (HR 0.56) and all-cause death (HR 0.80), lowered both LDL and hs-CRP, and increased physician-reported diabetes. It therefore does not isolate CRP lowering. AstraZeneca funded the trial.
- CANTOS — Randomized trial of 10,061 prior-heart-attack patients with hs-CRP at least 2 mg/L, median follow-up 3.7 years. The prespecified 150 mg canakinumab dose reduced recurrent cardiovascular events (HR 0.85) without lowering lipids, but fatal infections increased and overall mortality did not differ. Novartis funded the trial. The November 2024 FDA Ilaris label lists inflammatory-disease and gout-flare indications, not cardiovascular prevention.
- LoDoCo2 — Randomized trial of 5,522 people with chronic coronary disease, median follow-up 28.6 months. Low-dose colchicine reduced the composite cardiovascular endpoint from 9.6% to 6.8% (HR 0.69); noncardiovascular death was numerically higher (HR 1.51, 95% CI 0.99–2.31).
- COLCOT — Randomized trial of 4,745 people enrolled within 30 days after myocardial infarction, median follow-up 22.6 months. Colchicine reduced its composite cardiovascular endpoint from 7.1% to 5.5% (HR 0.77). The composite included urgent angina hospitalization with revascularization and does not show a lifespan benefit.
- CLEAR — Randomized 2-by-2 factorial trial of 7,062 people treated soon after myocardial infarction at 104 centers in 14 countries, median follow-up three years. Colchicine lowered CRP but not the primary cardiovascular endpoint (9.1% versus 9.3%; HR 0.99); diarrhea was more frequent. This acute-treatment result does not erase evidence from other settings.
- FDA Lodoco approval letter and prescribing label — Primary regulatory sources dated June 16, 2023. Approve colchicine 0.5 mg to reduce myocardial infarction, stroke, coronary revascularization and cardiovascular death in adults with established atherosclerotic disease (plaque buildup in arteries) or multiple cardiovascular risk factors; the label also documents contraindications and potentially serious interactions.
- 2025 ACC scientific statement and ACC summary — The statement reviews inflammation in cardiovascular disease and cautions that anti-inflammatory trials have not all succeeded. ACC’s summary describes it as advocating hs-CRP screening in primary and secondary prevention. A scientific statement is not the same document type as a clinical-practice guideline, and broad-screening outcome evidence remains incomplete.
Leave a Reply